Journal ArticleDOI
1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)
Michael A. Nauck,Ruth S. Weinstock,Guillermo E. Umpierrez,Bruno Guerci,Karen Boleyn,Zachary Skrivanek,Zvonko Milicevic +6 more
- Vol. 11, Iss: 3, pp 79-80
Reads0
Chats0
TLDR
This Phase 3, adaptive, double-blind, parallel arm trial compared dulaglutide (DU), a once-weekly, long-acting GLP-1-receptoragonist, with sitagliptin (sita) and placebo in metformin-treated patients with type 2 diabetes.Abstract:
This Phase 3, adaptive, double-blind, parallel arm trial compared dulaglutide (DU), a once-weekly, long-acting GLP-1-receptoragonist, with sitagliptin (sita) and placebo (PL) in metformin-treated patients with type 2 diabetes.read more
Citations
More filters
Journal ArticleDOI
Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
Zachary Skrivanek,Brenda Gaydos,Jenny Y. Chien,Mary Jane Geiger,Michael Heathman,Scott M. Berry,James H. Anderson,T. Forst,Zvonko Milicevic,Donald Berry +9 more
TL;DR: An adaptive, seamless, double‐blind study comparing dulaglutide, a once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor agonist, with placebo at 26 weeks and sitagliptin up to 104 weeks, whose results are presented here.
Journal ArticleDOI
Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad
TL;DR: La aparicion de 2 nuevos grupos terapeuticos, agonistas del receptor de GLP-1 e inhibidores del cotransportador sodio-glucosa tipo 2, that consiguen mejorar simultaneamente the HbA1c, el peso, y otros factores de riesgo cardiovascular sin producir hipoglucemias, representa un salto cualitativo